-
公开(公告)号：US11236121B2
公开(公告)日：2022-02-01
申请号：US16326977
申请日：2017-08-23
Applicant: Sage Therapeutics, Inc.
Inventor： Paul Steven Watson , Bret Berner , John Gregory Reid , Jian Wang , James J. Doherty , Stephen Jay Kanes
Abstract: This invention relates to a 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I) and crystalline solid forms and compositions thereof. Also disclosed herein are methods of making crystalline solid forms of the 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I) and methods of using the 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I) or crystalline solid forms, pharmaceutically acceptable salts, and pharmaceutically acceptable compositions thereof.
-
公开(公告)号：US20190350944A1
公开(公告)日：2019-11-21
申请号：US16423976
申请日：2019-05-28
Applicant: Sage Therapeutics, Inc.
Inventor： Francesco G. Salituro , Albert Jean Robichaud , Paul Steven Watson , William Hunke
IPC: A61K31/573 , A61K47/12 , A61K47/69 , A61K31/724 , A61K31/57 , C08B37/16 , A61K9/08 , A61K9/00
Abstract: Provided herein are pharmaceutically acceptable aqueous solution comprising a neuroactive steroid, a sulfobutyl ether beta cyclodextrin and a buffer; wherein: the solution is a stable solution between a pH of about 3 and about 9, e.g., at room temperature, for at least 1, 2, 3, 4 weeks; 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 months; 1, 2, 3 years or more; the buffer is present at a concentration of at least 0.1 mM; or the solution remains substantially free of impurities (e.g., the solution is substantially free of impurities at room temperature for at least 1, 2, 3, 4 weeks; 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 months; 1, 2, 3 years or more).
-
公开(公告)号：US20230399357A1
公开(公告)日：2023-12-14
申请号：US18455324
申请日：2023-08-24
Applicant: Sage Therapeutics, Inc.
Inventor： Paul Steven Watson , Bret Berner , John Gregory Reid , Jian Wang , James J. Doherty , Stephen Jay Kanes
CPC classification number: C07J43/003 , C07D231/14 , A61P37/00 , A61P25/22 , A61P25/18 , A61P25/24 , A61P25/00 , A61P25/08 , C07B2200/13
Abstract: This invention relates to a crystalline 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I),
and compositions thereof. Also disclosed herein are methods of making the same and methods of using the same.-
公开(公告)号：US20190177359A1
公开(公告)日：2019-06-13
申请号：US16326977
申请日：2017-08-23
Applicant: Sage Therapeutics, Inc.
Inventor： Paul Steven Watson , Bret Berner , John Gregory Reid , Jian Wang , James J. Doherty , Stephen Jay Kanes
Abstract: This invention relates to a 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I) and crystalline solid forms and compositions thereof. Also disclosed herein are methods of making crystalline solid forms of the 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I) and methods of using the 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I) or crystalline solid forms, pharmaceutically acceptable salts, and pharmaceutically acceptable compositions thereof.
-
5.发明公开公开(公告)号：US20230285417A1
公开(公告)日：2023-09-14
申请号：US18006141
申请日：2021-07-20
Applicant: Sage Therapeutics, Inc.
Inventor： Paul Steven Watson , Bret Berner , Padma Narayan , Xiaoxia Chen , Todd Anthony Stutzman , Jianing Meng , Carolyn Wilkerson , Raj Ramnik Jain
CPC classification number: A61K31/58 , A61K9/1694 , A61K9/1611 , A61K9/1635 , A61K9/1652 , A61K9/1623 , A61K9/1617 , A61K9/2009 , A61K9/2027 , A61K9/2054 , A61K9/2018 , A61K9/2013 , A61K9/485 , A61K9/4858 , A61K9/4866
Abstract: This invention relates to a 19-nor C3,3-disubstituted C21-pyrazolyl steroid of formula (I) and pharmaceutical compositions thereof. Also disclosed herein are methods of making the pharmaceutical compositions of the 19-nor C3,3-disubstituted C21-pyrazolyl steroid of formula (I) and methods of using the 19-nor C3,3-disubstituted C21-pyrazolyl steroid of formula (I) or crystalline solid forms, pharmaceutically acceptable salts, and pharmaceutically acceptable compositions thereof.
-
Patent Agency Ranking
公开(公告)号：US20220169674A1
公开(公告)日：2022-06-02
申请号：US17396464
申请日：2021-08-06
Applicant: Sage Therapeutics, Inc.
Inventor： Paul Steven Watson , Bret Berner , John Gregory Reid , Jian Wang , James J. Doherty , Stephen Jay Kanes
Abstract: This invention relates to a crystalline 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I), and compositions thereof. Also disclosed herein are methods of making the same and methods of using the same.
-
公开(公告)号：US20190008873A1
公开(公告)日：2019-01-10
申请号：US15737676
申请日：2016-06-17
Applicant: Sage Therapeutics, Inc.
Inventor： Francesco G. Salituro , Albert Jean Robichaud , Paul Steven Watson , William Hunke
IPC: A61K31/573 , A61K47/69 , A61K47/12 , A61K9/00 , A61K9/08
Abstract: Provided herein are pharmaceutically acceptable aqueous solution comprising a neuroactive steroid, a sulfobutyl ether beta cyclodextrin and a buffer; wherein: the solution is a stable solution between a pH of about 3 and about 9, e.g., at room temperature, for at least 1, 2, 3, 4 weeks; 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 months; 1, 2, 3 years or more; the buffer is present at a concentration of at least 0.1 mM; or the solution remains substantially free of impurities (e.g., the solution is substantially free of impurities at room temperature for at least 1, 2, 3, 4 weeks; 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 months; 1, 2, 3 years or more).
-
公开(公告)号：US11884696B2
公开(公告)日：2024-01-30
申请号：US17396464
申请日：2021-08-06
Applicant: Sage Therapeutics, Inc.
Inventor： Paul Steven Watson , Bret Berner , John Gregory Reid , Jian Wang , James J. Doherty , Stephen Jay Kanes
CPC classification number: C07J43/003 , A61P25/00 , A61P25/08 , A61P25/18 , A61P25/22 , A61P25/24 , A61P37/00 , C07D231/14 , C07B2200/13
Abstract: This invention relates to a crystalline 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I),
and compositions thereof. Also disclosed herein are methods of making the same and methods of using the same.-
公开(公告)号：US20230141665A1
公开(公告)日：2023-05-11
申请号：US18087870
申请日：2022-12-23
Applicant: Sage Therapeutics, Inc.
Inventor： Francesco G. Salituro , Albert J. Robichaud , Paul Steven Watson , William Hunke
IPC: A61K31/573 , A61K9/00 , A61K9/08 , A61K47/69 , A61K31/57 , C08B37/16 , A61K31/724 , A61K47/12
CPC classification number: A61K31/573 , A61K9/08 , A61K9/0019 , A61K31/57 , A61K31/724 , A61K47/12 , A61K47/6951 , C08B37/0015 , A61P25/24
Abstract: Provided herein are pharmaceutically acceptable aqueous solution comprising a neuroactive steroid, a sulfobutyl ether beta cyclodextrin and a buffer; wherein: the solution is a stable solution between a pH of about 3 and about 9, e.g., at room temperature, for at least 1, 2, 3, 4 weeks; 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 months; 1, 2, 3 years or more; the buffer is present at a concentration of at least 0.1 mM; or the solution remains substantially free of impurities (e.g., the solution is substantially free of impurities at room temperature for at least 1, 2, 3, 4 weeks; 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 months; 1, 2, 3 years or more).
-
10.发明申请公开(公告)号：US20230057130A1
公开(公告)日：2023-02-23
申请号：US17579541
申请日：2022-01-19
Applicant: Sage Therapeutics, Inc.
Inventor： Paul Steven Watson , Bret Berner , Padma Narayan , Xiaoxia Chen , Todd Anthony Stutzman , Jianing Meng , Carolyn Wilkerson , Raj Ramnik Jain
Abstract: This invention relates to a 19-nor C3,3-disubstituted C21-pyrazolyl steroid of formula (I) and pharmaceutical compositions thereof. Also disclosed herein are methods of making the pharmaceutical compositions of the 19-nor C3,3-disubstituted C21-pyrazolyl steroid of formula (I) and methods of using the 19-nor C3,3-disubstituted C21-pyrazolyl steroid of formula (I) or crystalline solid forms, pharmaceutically acceptable salts, and pharmaceutically acceptable compositions thereof.
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.019 seconds)
